News
IGC
0.2970
-1.62%
-0.0049
Weekly Report: what happened at IGC last week (0406-0410)?
Weekly Report · 21h ago
IGC Pharma Is Maintained at Buy by Ascendiant Capital
Dow Jones · 5d ago
IGC Pharma Price Target Raised to $5.25/Share From $5.00 by Ascendiant Capital
Dow Jones · 5d ago
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25
Benzinga · 5d ago
IGC announces activation of new clinical trial sate for Phase 2 CALMA trial
TipRanks · 6d ago
Weekly Report: what happened at IGC last week (0330-0403)?
Weekly Report · 04/06 09:36
IGC Pharma Launches National Media Partnership to Boost Visibility
TipRanks · 03/31 00:14
IGC Pharma enters national media partnership with New to The Street
TipRanks · 03/30 12:38
Weekly Report: what happened at IGC last week (0323-0327)?
Weekly Report · 03/30 09:36
IGC Pharma, New to The Street launch 12-part national media partnership
TipRanks · 03/25 12:20
Weekly Report: what happened at IGC last week (0316-0320)?
Weekly Report · 03/23 09:34
IGC Pharma reports results
Seeking Alpha · 03/19 19:02
Congressman introduces bill for cannabis businesses to list on stock exchanges
TipRanks · 03/19 15:20
'Medicare CBD Pilot Will Allow Some THC in Products'- Cannabis Wire
Benzinga · 03/19 14:30
IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate
Benzinga · 03/19 13:25
IGC Pharma reports 9-month revenue $969K
TipRanks · 03/19 13:12
IGC Pharma to showcase AI platform with ADDI at ADPD 2026
TipRanks · 03/18 13:10
Study says cannabis shows little benefit for mental disorders, Reuters says
TipRanks · 03/17 10:40
Weekly Report: what happened at IGC last week (0309-0313)?
Weekly Report · 03/16 09:34
IGC Pharma Secures New Debt Financing for Liquidity
TipRanks · 03/12 10:43
More
Webull provides a variety of real-time IGC stock news. You can receive the latest news about IGC Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IGC
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.